Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases

Cancer Genetics and Cytogenetics

Volumn 177, Issue 1, 2007, Pages 64-69

  Weisser, Martin ^a   Haferlach, Claudia ^b   Haferlach, Torsten ^b   Schnittger, Susanne ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTARABINE; MITOXANTRONE; RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DISEASE COURSE; EVI1 GENE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ACUTE DISEASE; CYTOGENETIC ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 34547658148     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.05.003     Document Type: Article

References (30)

1. Schnittger S., Weisser M., Schoch C., Hiddemann W., Haferlach T., and Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102 (2003) 2746-2755
2. Buonamici S., Ottaviani E., Testoni N., Montefusco V., Visani G., Bonifazi F., Amabile M., Terrangna C., Ruggeri D., Piccaluga P.P., Isidori A., Malagola M., Baccarani M., Tura S., and Martinelli G. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 99 (2002) 443-449
3. Guerrasio A., Pilatrino C., De Micheli D., Cilloni D., Serra A., Gottardi E., Parziale A., Marmont F., Diverio D., Divona M., Lo Coco F., and Saglio G. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 16 (2002) 1176-1181
4. Marcucci G., Caligiuri M.A., Dohner H., Archer K.J., Schlenk R.F., Dohner K., Maghraby E.A., and Bloomfield C.D. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 15 (2001) 1072-1080
5. Libura M., Asnafi V., Tu A., Delabesse E., Tigaud I., Cymbalista F., Bennaceur-Griscelli A., Villarese P., Solbu G., Hagemeijer A., Beldjord K., Termine O., and Macintyre E. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood 102 (2003) 2198-2204
6. Schnittger S., Schoch C., Kern W., Hiddemann W., and Haferlach T. FLT3 length mutations as marker for follow-up studies in acute myeloid leukemia. Acta Haematologica 112 (2004) 68-78
7. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., and Schnittger S. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19 (2005) 1416-1423
8. Garg M., Moore H., Tobal K., and Liu Yin J.A. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123 (2003) 49-59
9. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 11 (1997) 2022-2031
10. Jolkowska J., and Witt M. The EVI-1 gene-its role in pathogenesis of human leukemias. Leuk Res 24 (2000) 553-558
11. Morishita K., Parganas E., William C.L., Whittaker M.H., Drabkin H., Oval J., Taetle R., Valentine M.B., and Ihle J.N. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 89 (1992) 3937-3941
12. Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI1. Oncogene 23 (2004) 4263-4269
13. Russell M., Thompson F., Spier C., and Taetle R. Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. Leukemia 7 (1993) 1654-1657
14. Russell M., List A., Greenberg P., Woodward S., Glinsmann B., Parganas E., Ihle J., and Taetle R. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 84 (1994) 1243-1248
15. Xi Z.F., Russell M., Woodward S., Thompson F., Wagner L., and Taetle R. Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia. Leukemia 11 (1997) 212-220
16. Dreyfus F., Bouscary D., Melle J., Ribrag V., Guesnu M., and Varet B. Expression of the Evi-1 gene in myelodysplastic syndromes. Leukemia 9 (1995) 203-205
17. van Waalwijk B., van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., Valk P.J., van der Poel-van de Luytgaarde S., Hack R., Slater R., Smit E.M., Beverloo H.B., Verhoef G., Verdonck L.F., Ossenkoppele G.J., Sonneveld P., de Greef G., Löwenberg B., and Delwel R. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101 (2003) 837-845
18. Ohyashiki J.H., Ohyashiki K., Shimamoto T., Kawakubo K., Fujimura T., Nakazawa S., and Toyama K. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. Blood 85 (1995) 3713-3718
19. Langabeer S.E., Rogers J.R., Harrison G., Wheatley K., Walker H., Bain B.J., Burnett A.K., Goldstone A.H., Linch D.C., and Grimwade D. EVI1 expression in acute myeloid leukaemia. Br J Haematol 112 (2001) 208-211
20. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (1976) 451-458
21. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78 (1991) 325-329
22. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon, France
23. Schoch C., Schnittger S., Bursch S., Gerstner D., Hochhaus A., Berger U., Hehlmann R., Hiddemann W., and Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16 (2002) 53-59
24. ISCN. Guidelines for Cancer Cytogenetics (supplement to An International System for Human Cytogenetic Nomenclature). In: Mitelman F. (Ed) (1995), S. Karger, Basel
25. Weisser M., Kern W., Schoch C., Tschulik C., Hiddemann W., Haferlach T., and Schnittger S. Reverse transcriptase polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia. Leuk Lymph 47 (2006) 2645-2647
26. Emig M., Saussele S., Wittor H., Weisser A., Reiter A., Willer A., Berger U., Hehlmann R., Cross N.C., and Hochhaus A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13 (1999) 1825-1832
27. Repp R., Borkhardt A., Haupt E., Kreuder J., Brettreich S., Hammermann J., Nishida K., Harbott J., and Lampert F. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia 9 (1995) 210-215
28. Weisser M., Kern W., Schoch C., Hiddemann W., Haferlach T., and Schnittger S. Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 90 (2005) 881-889
29. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
30. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., Pettenati M.J., Patil S.R., Rao K.W., Watson M.S., Koduru P.R., Moore J.O., Stone R.M., Mayer R.J., Feldman E.J., Davey F.R., Schiffer C.A., Larson R.A., Bloomfield C.D., Rees J., Hann I., Stevens R., Burnett A., and Goldstone A. Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336